PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer
Abstract
PROTACs based on two selective, FDA approved, CDK4/6 inhibitors were formed. These PROTACs at nanomolar concentrations deplete CDK4/6.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2019
- Source ID
- 10.1039/c9cc00163h
Entities
People
- Bosheng Zhao
- Kevin Burgess
Organizations
- Cancer Prevention and Research Institute of Texas
- National Institutes of Health
- National Science Foundation
- Robert A. Welch Foundation
- Texas A&M University
- United States Army
- United States Department of Defense
- Yusuf Hamied Department of Chemistry